4995 Murphy Canyon Road
Suite 300
San Diego, CA 92123
United States
760 471 8536
https://www.conduitpharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 7
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. David Joszef Tapolczay | CEO & Director | 419,8k | S.O. | 1959 |
Mr. Adam Sragovicz | Chief Financial Officer | 116,67k | S.O. | 1970 |
Dr. Joanne M. Holland | Chief Scientific Officer | S.O. | S.O. | 1975 |
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
L’ISS Governance QualityScore de Conduit Pharmaceuticals Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..